Consequently, BMX inhibition by ibrutinib specifically disrupts GSCs and suppresses GBM tumor growth, while exhibiting minimal effects on neural progenitor cells activating JAK2-mediated STAT3 [110]. The gene discussed is STAT3; the disease is glioblastoma.